Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 jul 2013 - 07:33
Statutaire naam
Galapagos NV
Titel
Galapagos receives €2.4 million IWT grant for psoriasis research
Bericht
Mechelen, Belgium; 8 July 2013 - Galapagos NV (Euronext: GLPG) announced today that it has been awarded a €2.4 million TGO (transformational medical research) grant from the Flemish agency for Innovation by Science and Technology (IWT) for psoriasis research and development. The goal of this 4-year project is to bring a novel mode of action compound into the clinic that might lead to a safe and effective treatment for patients suffering from psoriasis.
Psoriasis is a common skin disease with a high impact on well-being and for which options for patient are currently limited. Psoriasis is a chronic disease, affecting approximately 3% of the population. It has no final cure and therefore represents a high burden to quality of life.
Datum laatste update: 10 februari 2025